ES2059377T3 - Pirazoles 1,5-diaril-3-sustituidos farmacologicamente activos y procedimiento para sintetizar los mismos. - Google Patents

Pirazoles 1,5-diaril-3-sustituidos farmacologicamente activos y procedimiento para sintetizar los mismos.

Info

Publication number
ES2059377T3
ES2059377T3 ES87304720T ES87304720T ES2059377T3 ES 2059377 T3 ES2059377 T3 ES 2059377T3 ES 87304720 T ES87304720 T ES 87304720T ES 87304720 T ES87304720 T ES 87304720T ES 2059377 T3 ES2059377 T3 ES 2059377T3
Authority
ES
Spain
Prior art keywords
diaril
pharzacologically
synthesizing
procedure
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87304720T
Other languages
English (en)
Inventor
Michael Paul Wachter
Michael Paul Ferro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Application granted granted Critical
Publication of ES2059377T3 publication Critical patent/ES2059377T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A PIRAZOLES 1,5-DIARIL-3-SUSTITUIDOS, A UN METODO PARA SU PREPARACION, A COMPOSICIONES QUE LOS CONTIENEN Y A METODOS PARA SU EMPLEO. LOS CITADOS PIRAZOLES SON UTILES PARA EL TRATAMIENTO DE DESORDENES INFLAMATORIOS Y CARDIOVASCULARES EN MAMIFEROS.
ES87304720T 1986-05-29 1987-05-28 Pirazoles 1,5-diaril-3-sustituidos farmacologicamente activos y procedimiento para sintetizar los mismos. Expired - Lifetime ES2059377T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86799686A 1986-05-29 1986-05-29
US07/042,661 US4826868A (en) 1986-05-29 1987-04-29 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use

Publications (1)

Publication Number Publication Date
ES2059377T3 true ES2059377T3 (es) 1994-11-16

Family

ID=26719497

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87304720T Expired - Lifetime ES2059377T3 (es) 1986-05-29 1987-05-28 Pirazoles 1,5-diaril-3-sustituidos farmacologicamente activos y procedimiento para sintetizar los mismos.

Country Status (21)

Country Link
US (1) US4826868A (es)
EP (1) EP0248594B1 (es)
JP (1) JP2512751B2 (es)
KR (1) KR960007163B1 (es)
CN (1) CN1028227C (es)
AU (1) AU596844B2 (es)
CA (1) CA1337122C (es)
DE (2) DE3788244T2 (es)
DK (1) DK170202B1 (es)
ES (1) ES2059377T3 (es)
FI (1) FI94340C (es)
HK (1) HK14094A (es)
HU (1) HU221300B1 (es)
IE (1) IE63856B1 (es)
IL (1) IL82671A0 (es)
LU (1) LU90829I2 (es)
NL (1) NL300057I2 (es)
NO (2) NO172236C (es)
NZ (1) NZ220353A (es)
PH (1) PH25126A (es)
PT (1) PT84964B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898952A (en) * 1987-05-29 1990-02-06 Ortho Pharmaceutical Corporation Regioselective synthesis of a 1,5-disubstituted pyrazole
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
JPS63307841A (ja) * 1987-05-29 1988-12-15 オーソ・フアーマシユーチカル・コーポレーシヨン １，５‐ジ置換ピラゾール類の製造法
CA1334975C (en) * 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2052950A1 (en) * 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5260458A (en) * 1991-09-26 1993-11-09 Ortho Pharmaceutical Corporation 2-oxo tetrahydrofuran compounds
US5117054A (en) * 1991-09-26 1992-05-26 Ortho Pharmaceutical Corporation N-hydroxy, N-methyl propanamides
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5387602A (en) * 1993-08-30 1995-02-07 Ortho Pharmaceutical Corporation 1.5-diphenyl-3-(N-hydroxycarbamoyloxyalkyl)pyrazoles
IL111613A0 (en) * 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
CA2277954A1 (en) * 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
AU3815495A (en) * 1994-11-08 1996-05-31 Eisai Co. Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
JPH10508032A (ja) * 1994-12-13 1998-08-04 ユーロ−セルティーク，エス．エイ． アリールチオキサンチン類
EP0799040B1 (en) * 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
IL142341A0 (en) * 1999-08-03 2002-03-10 Ortho Mcneil Pharm Inc Process for preparing 1,5-diaryl-3-substituted pyrazoles
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
WO2004016592A1 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004016741A2 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
AU2003275637A1 (en) * 2002-10-24 2004-05-13 Wakamoto Pharmaceutical Co., Ltd. Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase
WO2004050632A1 (en) * 2002-12-02 2004-06-17 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives useful as cox-i inhibitors
EP1613614A2 (en) * 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20050020565A1 (en) * 2003-07-02 2005-01-27 Jones Todd K. CCK-1 receptor modulators
WO2005005393A2 (en) * 2003-07-02 2005-01-20 Janssen Pharmaceutica N.V. Cck-1 receptor modulators
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
WO2005037271A2 (en) * 2003-10-17 2005-04-28 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activated k channel opener
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060004195A1 (en) * 2004-06-30 2006-01-05 Xiaohu Deng Alpha,beta-unsaturated esters and acids by stereoselective dehydration
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
SI2124944T1 (sl) * 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
WO2011161645A1 (en) * 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CA2803880C (en) * 2010-06-28 2018-09-25 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation
US8492424B2 (en) * 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2861562B1 (en) * 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755924A (fr) * 1969-09-12 1971-02-15 Byk Gulden Lomberg Chem Fab Derives d'acide pyrazole-4-acetique, leur procede de preparation et medicaments en contenant
GB1373212A (en) * 1970-12-07 1974-11-06 Wyeth John & Brother Ltd Pyrazole compounds
US3974176A (en) * 1973-08-16 1976-08-10 Byk-Gulden Lomberg Chemische Fabrik Gmbh Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them
DE2633992A1 (de) * 1975-08-08 1978-02-09 Schering Ag Neue pyrazol-derivate, ihre herstellung und verwendung
DE2906252A1 (de) * 1979-02-19 1980-08-28 Merck Patent Gmbh Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
DE3205187A1 (de) * 1982-02-13 1983-08-25 Hoechst Ag, 6230 Frankfurt Substituierte phenylpyrazolderivate, verfahren zu ihrer herstellung, arzneimittel auf basis dieser verbindungen, sowie deren verwendung

Also Published As

Publication number Publication date
DK273587D0 (da) 1987-05-27
NO872228L (no) 1987-11-30
NO172236C (no) 1993-06-23
KR960007163B1 (ko) 1996-05-29
DE3788244D1 (de) 1994-01-05
FI94340C (fi) 1995-08-25
CN87103953A (zh) 1987-12-09
PH25126A (en) 1991-02-19
EP0248594A3 (en) 1988-11-17
HU221300B1 (en) 2002-09-28
CA1337122C (en) 1995-09-26
PT84964A (en) 1987-06-01
NL300057I2 (nl) 2002-01-02
HUT68247A (en) 1995-06-28
FI872379A0 (fi) 1987-05-28
FI872379A7 (fi) 1987-11-30
HK14094A (en) 1994-03-04
LU90829I2 (fr) 2001-11-12
NO172236B (no) 1993-03-15
DE10199049I2 (de) 2003-01-09
EP0248594A2 (en) 1987-12-09
DE3788244T2 (de) 1994-04-14
DK170202B1 (da) 1995-06-12
NZ220353A (en) 1989-05-29
CN1028227C (zh) 1995-04-19
US4826868A (en) 1989-05-02
AU7360887A (en) 1987-12-10
DE10199049I1 (de) 2002-01-10
IL82671A0 (en) 1987-11-30
JP2512751B2 (ja) 1996-07-03
JPS6322080A (ja) 1988-01-29
FI94340B (fi) 1995-05-15
EP0248594B1 (en) 1993-11-24
AU596844B2 (en) 1990-05-17
IE63856B1 (en) 1995-06-14
NO2001016I1 (no) 2001-10-01
KR870011100A (ko) 1987-12-21
DK273587A (da) 1987-11-30
PT84964B (pt) 1990-02-08
IE871403L (en) 1987-11-29
NO872228D0 (no) 1987-05-27
NL300057I1 (nl) 2001-12-01

Similar Documents

Publication Publication Date Title
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
BG40654A3 (bg) Метод за получаване на циклоалкилтриазоли
ES2150567T3 (es) Antagonistas del factor de liberacion de la corticotropina.
ES2037013T3 (es) Procedimiento para preparar tieno-1,4-diazepinas.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES520988A0 (es) Procedimiento para la preparacion de nuevos 6,11-dihidro-dibenzo-(b,e)-tiepin-11-n-alcohilnorescopin-eteres.
BG31646A3 (bg) Метод за получаване на фенетаноламини
ATE26115T1 (de) Substituierte 8-phenylxanthine.
ES2056105T3 (es) Di-t-butilfenoles sustituidos.
BG37526A3 (bg) Метод за получаване на естери на малоновата киселина
FI872379A0 (fi) Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi
BG32851A3 (bg) Метод за получаване на 3,4,5,6-тетрахидро-2н- -1-бензоксецини
DK499679A (da) Fremgangsmaade til fremstilling af hydroxypropyl-triazoler
YU46223B (sh) Postupak za dobivanje 1-/4-aminofenil/-4-metil-7,8-metilendioksi-3,4-dihid ro-5h-2,3-benzodiazepina
ES2059416T3 (es) 1,4-dihidropiridina-enantiomeros.
IL58299A (en) Fluorine-containing 1,4-dihydropyridine derivatives,their production and their medicinal use
BG35330A3 (bg) Метод за получаване на 3-йодметилцефалоспорини
BG31492A3 (bg) Метод за получаване на фенетаноламини
BG41126A3 (en) Method for preparing benzamides
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
IT1247796B (it) Derivati arilvinilamidici e procedimento per la loro preparazione
BG36932A3 (bg) Метод за получаване на 1-(3-хидрокси-4-метаксибензоил)-3- хидрокси-2-пиролидинон
BG40803A3 (bg) Метод за получаване на арилциклобутилалкиламинови производни
BG38638A3 (bg) Метод за получаване на арилциклобутил-аминопроизводни
ES8401064A1 (es) Procedimiento para la obtencion de azolil-fenoxi-tetrahidrofuran-2-iliden-metanos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 248594

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: TEPOXALIN (ZUBRIN)

Spc suppl protection certif: C200100025

Filing date: 20010911

SPCG Supplementary protection certificate granted

Free format text: TEPOXALIN (ZUBRIN).

Spc suppl protection certif: C200100025

Filing date: 20010911

Expiry date: 20120528

Effective date: 20040614